Australian clinical-stage immuno-oncology company Imugene (ASX:IMU) has announced the dosing of the first patient in the intravenous infusion combination arm of its Phase 1 onCARlytics (CF33-CD19) clinical trial. …
Imugene doses the first patient in pioneering Phase 1 onCARlytics trial
June 24, 2024 Australian Biotech
Latest Video
New Stories
-
Medicines Australia backs focus on listings and productivity in government brief
July 3, 2025 - - Latest News -
AusBiotech seeking a head of investment to drive sector growth
July 3, 2025 - - Australian Biotech -
What's the point of pretending that Australia doesn't free-ride on US innovation?
July 3, 2025 - - Latest News -
Framework pushes genomics funding to a review that is mostly silent on it
July 3, 2025 - - Latest News -
Draft 'National Health Genomics Policy Framework' out for consultation
July 3, 2025 - - Latest News -
MedAdvisor announces agreement confirming the sale of Australian business
July 3, 2025 - - Latest News -
GBMA announces planned departure of long-standing CEO
July 2, 2025 - - Latest News